Another study, by Wang et al., in advanced NSCLC patients (n = 149), also demonstrated that pre-treatment levels of plasma exosomal PD-L1 associated with clinical response to anti-PD-1 inhibitors [67]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.